Jubilant Pharmova Ltd.’s revenue in Q4FY23 rose 10% to ₹ 1,678 crores. Consolidated Loss After Tax came at ₹ 101 crores in Q4FY23.
Jubilant Pharmova Q4FY23; Reported Losses
Tags: Radiopharma
Related Post
- Amanta Healthcare Limited reports steady Q3 FY26 growth; 9M profit rises on margin expansion and deleveraging
Amanta Healthcare Limited (NSE: AMANTA, BSE: 544502) reported steady revenue growth and improved profitability for…
-
India Pesticides Limited posts strong Q3 FY26 growth as exports and domestic demand lift earnings
India Pesticides Limited (NSE: IPL, BSE: 543311) reported strong growth in revenue and profit for…
-
Aarti Pharmalabs Limited reports sequential margin recovery in Q3 FY26 as CDMO transit impact weighs on revenue
Aarti Pharmalabs Limited (NSE: AARTIPHARM, BSE: 543748) reported a sequential improvement in operating performance in…